# Kisspeptin Research: The Mechanism and the Human Trial Record > Kisspeptin research, traced from the KISS1 discovery to the human trials: GnRH activation, LH and testosterone in men, LH-pulse restoration, and the IVF OHSS-free trigger — fully cited. Mechanism, key studies, and the most recent data — each finding logged to its source and reported as study-attributed. ## Start here Kisspeptin research runs along one clear thread: this molecule turns on the reproductive system from the top. Scientists found the KISS1 gene in 1996 while studying how cancers spread, then realized in 2003 that the same gene is the master switch for puberty and fertility. Since then, studies have tested giving kisspeptin to healthy volunteers and patients to see how their hormones respond. The pattern is consistent: kisspeptin reliably pushes up LH (the pituitary hormone that drives ovulation and testosterone), and in the right setting it can restore lost menstrual cycles or trigger egg maturation for IVF more safely than older methods. The catch is that pushing the dose continuously stops working — the receptor tunes it out within days. All of the doses below are what researchers gave to specific groups by a specific route; none is a recommendation. ## The KISS1 discovery and the puberty switch KISS1 entered the literature as a metastasis-suppressor gene in human melanoma in 1996: introducing it into metastatic C8161 melanoma cells suppressed their spread in nude mice without abolishing the tumor's growth, and the gene took its KiSS abbreviation from Hershey, Pennsylvania, where it was found [8]. A 2006 review synthesized how KISS1/kisspeptin signalling through GPR54 restrains metastatic spread across cancer models [9]. The reproductive role landed in 2003. Loss-of-function mutations in GPR54 caused autosomal-recessive idiopathic hypogonadotropic hypogonadism with failure of puberty in humans, and Gpr54-knockout mice reproduced the phenotype — establishing kisspeptin-GPR54 signalling as essential for reproductive maturation [1]. The mirror-image genetics followed: a heterozygous gain-of-function GPR54 mutation (Arg386Pro) was found in a girl with central precocious puberty, with the mutant receptor showing prolonged responsiveness to kisspeptin [10], and an inactivating KISS1 mutation in a consanguineous family caused hypogonadotropic hypogonadism, the first human evidence that the peptide itself — not only its receptor — is required for puberty [11]. ## The GnRH-neuron mechanism At the cellular level, kisspeptin excites GnRH neurons directly. In mouse brain-slice electrophysiology, 100 nM kisspeptin depolarized GnRH neurons by 6 ± 1 mV and increased firing rate by 87 ± 4% in about 75% of adult GnRH neurons, through a phospholipase C / IP3 / intracellular-calcium cascade that closed potassium channels and opened non-selective cation channels [2]. That defined the ion-channel route by which the kisspeptin signal becomes pulsatile GnRH output. The [kisspeptin mechanism of action](/mechanism-of-action) page lays out the full cascade. ## LH, pulse frequency, and testosterone in men In healthy men, intravenous kisspeptin-10 produced maximal LH stimulation at a 1 ug/kg bolus, raising LH from 4.1 to 12.4 IU/L at 30 minutes; a continuous infusion at 1.5 ug/kg/h raised mean LH from 5.2 to 14.1 IU/L and increased LH pulse frequency from 0.7 to 1.0 pulses/h, while a higher 4 ug/kg/h infusion raised serum testosterone from 16.6 to 24.0 nmol/L [3]. The result identified kisspeptin-10 as a potent, dose-dependent LH stimulator in men — and, because raising pulse frequency matters as much as raising the level, a tool for probing how the pulse generator works. ## Restoring LH pulses in hypothalamic amenorrhea In women with hypothalamic amenorrhea, continuous intravenous kisspeptin-54 (0.01-1.00 nmol/kg/h) restored pulsatile LH secretion: LH pulses rose from 1.6 to 5.0 per 8 hours (about three-fold) and pulse secretory mass from 3.92 to 23.44 IU/L (about six-fold) versus vehicle — though the highest dose produced tachyphylaxis over the infusion [4]. In healthy women in the early follicular phase, subcutaneous kisspeptin-54 (0.3 and 1.0 nmol/kg/h) increased LH and FSH, with the LH response correlating positively with basal estradiol [14], showing the response is gated by the prevailing hormonal state. ## The IVF oocyte-maturation trigger and OHSS The clearest clinical payoff is in IVF. In a Phase 2 randomized trial of 60 women at high risk of ovarian hyperstimulation syndrome (OHSS — a potentially serious over-response to fertility stimulation), a single subcutaneous kisspeptin-54 dose (3.2-12.8 nmol/kg) triggered oocyte maturation in 95% of women with no case of moderate, severe, or critical OHSS; the highest live-birth rate (62%) followed the 9.6 nmol/kg dose [5]. Because kisspeptin triggers the body's own short LH surge rather than mimicking a sustained one, it offers a mechanistically safer alternative to older triggers for OHSS-prone patients. ## Recent data: the intranasal route and the clinical map Delivery is moving beyond the needle. In 2025, intranasal kisspeptin-54 (primary dose 12.8 nmol/kg) rapidly stimulated LH release in healthy men (+4.4 IU/L), healthy women (+1.4 IU/L), and women with hypothalamic amenorrhea (+4.4 IU/L) without adverse events, and the nasal-spray formulation was stable for up to 60 days at 4 °C — the first clinical demonstration of effective non-invasive kisspeptin delivery [6]. A 2025 systematic review (databases searched through February 2023) catalogued 29 interventional clinical trials across secondary amenorrhea, puberty regulation, ovarian function, trophoblast invasion, fertility regulation, parturition, and lactation, noting considerably fewer side effects than comparators — and confirming that no kisspeptin product is regulatory-approved [7]. ## Open questions and a vascular signal Two threads temper the picture. A 2018 study found divergent LH responses to a kisspeptin challenge in children with delayed puberty, a subset showing robust adult-like responses — suggesting kisspeptin responsiveness may help characterize how far the pubertal axis has matured [12]. And in atherosclerosis-prone ApoE-/- mice, four weeks of kisspeptin-10 infusion accelerated aortic plaque development and instability with elevated pro-inflammatory cytokines, reversed by a GPR54 antagonist — a cardiovascular signal in a rodent model, distinct from kisspeptin's reproductive actions and uncharacterized in humans [13]. A separate hypothesis-review linked arcuate KNDy neurons (kisspeptin/neurokinin B/dynorphin) to thermoregulation, offering a neuroendocrine mechanism for menopausal hot flushes [15]. --- A discovery-first reading of the Kisspeptin record — the KISS1 gene traced from metastasis suppressor to the master switch above GnRH, every human finding logged to its source and the not-approved, not-a-supplement status held in plain sight; no clinic behind the cascade, and nothing here dosed, dispensed, or sold.